Century Therapeutics, Inc. IPSC
Century Therapeutics, Inc. (Nasdaq: IPSC) is an immunology/inflammation drug developer. Its lead program, CNTY-101 (iPSC-derived allogeneic CD19 CAR-iNK), is in Phase 1 for B-cell malignancies / autoimmune (CARAMEL investigator-sponsored Phase 1/2). Its next catalyst on record is CNTY-813: IND submission (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: CNTY-813 — IND submission (Q4 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| CNTY-101 | CD19+ B-cell disease (CARAMEL Phase 1/2, investigator-sponsored) | cell therapy | Phase 1 |
| CNTY-813 | type 1 diabetes | cell therapy | Pre-clinical |
| CNTY-308 | B-cell-mediated diseases (CD19 CAR-iT) | cell therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.